Category: Side Effect: Joint Problems (arthralgia, joint pain, arthritis)
-
Gadolinium Toxicity Risks Higher For Children, Pregnant Women, And People Receiving Multiple Doses
Gadolinium Deposition Disease And Neurological Adverse Reactions Associated With The Use Of Gadolinium-Based Contrast Agents (Posted by Tom Lamb at DrugInjuryWatch.com) In May 2018 Health Canada announced the results of its second…
-
Gadolinium-Based Contrast Agents: Gadolinium Retention Higher For Linear Gadolinium Agents Than Macrocyclic Agents
Gadolinium Retention Can Cause Various Medical Problems With General Diagnosis Label Of Gadolinium Deposition Disease (Posted by Tom Lamb at DrugInjuryWatch.com) There are two types of gadolinium based contrast agents (GBCAs): linear and…
-
Gadolinium Retention Warnings Added To Drug Labels For Gadolinium Contrast Agents Used During MRI / MRA
Label Changes Announced By FDA In December 2017 Finally Approved For Magnevist, Omniscan, And Other GBCAs In April 2018 (Posted by Tom Lamb at DrugInjuryWatch.com) Gadolinium based contrast agents (GBCAs) are substances…
-
Some MRI Contrast Agents Containing Gadolinium Can Cause Problems Ranging From “Brain Fog” To Permanent Disability
Gadolinium Deposition Disease Symptoms Typically Begin Couple Of Months After Use And Can Continue For Many Years Without Any Diagnosis (Posted by Tom Lamb at DrugInjuryWatch.com) During MRI and MRA procedures patients…
-
New FDA Warning That Januvia, Onglyza, Tradjenta, And Nesina Are Associated With “joint pain that can be severe and disabling”
Label Changes About Side Effects For These Type 2 Diabetes Medicines In The Drug Class Called Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Posted by Tom Lamb at DrugInjuryWatch.com) In August 2015 the FDA announced…